We are international

Myeloma Minute
February 12, 2015
February 12, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

This week's question: What does 'dysplasia' mean within the bone marrow report?


Multiple Myeloma Bone Study


Upcoming Events

Saturday, March 7, 2015
Regional Community Workshop Denver, Colorado

Saturday, March 7, 2015
Zumba for Multiple Myeloma
St. Augustine, Florida

Saturday, March 14, 2015 Regional Community Workshop
San Diego, California

Saturday, March 14, 2015
Virginia Beach, Virginia

Friday - Saturday,
March 27 - 28, 2015

Patient & Family Seminar
San Francisco, California

Saturday, April 11, 2015
Myeloma Center Workshop
Dallas, Texas

Watch the IMF Mambo for Myeloma & Support This Challenge

Shop the IMF Mall for Valentine's Day






Measles and Myeloma: Should You Be Concerned?

With a recent measles outbreak in the US placing attention on the disease and the measles vaccine, IMF Chairman Dr. Brian Durie weighs in on the measles and myeloma. For myeloma patients, the chance of contracting the measles is low because most adults were inoculated when they were children and are therefore immune. In fact, many myeloma patients were ineligible for Dr. Stephen Russell’s Mayo Clinic measles virotherapy clinical trial because they were immune to the disease. CLICK HERE to read Dr. Durie’s blog.


Ixazomib Improves Progression-Free Survival in Relapsed or Refractory Myeloma


It was good news for myeloma patients this week as ixazomib, an oral proteasome inhibitor in development by Takeda, was shown to improve progression-free survival in relapsed and/or refractory myeloma in the international phase III clinical trial TOURMALINE-MM1. In an interim analysis of the trial, patients treated with ixazomib plus lenalidomide (Revlimid®) and dexamethasone lived without their disease worsening for a significantly longer time compared to patients who received placebo plus lenalidomide/dexamethasone. Takeda intends to submit these results to health authorities around the world for regulatory review. READ MORE


Updated Glossary of Myeloma Terms & Definitions


Have you ever felt like you were hearing a foreign language during a visit to the doctor? Myeloma brings many new concepts and medical terms to understand, including your body’s anatomy and systems, types of treatment, clinical trial terminology, and more. It can feel overwhelming at times, but the IMF is here to serve as your personal translator with handy resources, such as a newly updated glossary of myeloma terms and definitions. CLICK HERE to read and bookmark the new glossary.


Share Your Story for Myeloma Awareness Month


With less than a month until March begins, the IMF is getting the ball rolling on Myeloma Awareness Month (#MAM). Sharing your story with even one person can help spread awareness, but with the internet at your fingertips, your story has the potential to inspire and educate thousands. Stories from patients and caregivers can inspire others to get their symptoms checked or go for a screening they’d been putting off. These stories also provide hope and support to people who may be going through difficult times. CLICK HERE to share your story, a lesson, or a piece of advice.


The Importance of Dogs to Cancer Patients


Anyone who has been touched by cancer knows that drug therapies and physical treatments are only one part of the road to recovery. Another key factor is emotional health, and a new study in the "Journal of Community and Supportive Oncology" shows that therapy dogs boost cancer patients’ morale during a seemingly impossible time, improving overall outcomes for those patients. CLICK HERE to read the study.

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles